Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.71 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.67 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.54 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.54 |
| ▸ | KDR | P35968 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2641988 | 0.90 | FGFR1 (0.59) | HTTFGFR1KDRMAPTKMT2A | |
| SCHEMBL20180561 | 0.88 | HTT (0.59) | HTTFGFR1MAPTKMT2APTK2B | |
| SCHEMBL16158540 | 0.88 | FGFR1 (0.83) | HTTFGFR1 | |
| SCHEMBL2642001 | 0.88 | FGFR1 (0.83) | HTTFGFR1 | |
| SCHEMBL2642019 | 0.88 | FGFR1 (0.60) | HTTFGFR1 | |
| SCHEMBL3417304 | 0.88 | HTT (0.78) | HTTFGFR1 | |
| SCHEMBL16158486 | 0.86 | FGFR1 (0.59) | HTTFGFR1KDRMAPTKMT2A | |
| SCHEMBL13045092 | 0.85 | FGFR1 (0.57) | HTTFGFR1MAPTKMT2APTK2B | |
| SCHEMBL23266576 | 0.84 | FGFR1 (0.60) | HTTFGFR1 | |
| SCHEMBL18731746 | 0.84 | HTT (0.79) | HTTFGFR1MAPTKMT2APTK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040077634-A1 | Treatment of diseases characterized by excessive or insufficient cell death | NEUROSEARCH A/S (DK) | 2004-04-22 | — | — | US | claimed |
| EP-1361874-A1 | TREATMENT OF DISEASES CHARACTERIZED BY EXCESSIVE OR INSUFFICIENT CELL DEATH | NEUROSEARCH A/S (DK) | 2003-11-19 | — | — | EP | claimed |
| WO-2002064128-A1 | TREATMENT OF DISEASES CHARACTERIZED BY EXCESSIVE OR INSUFFICIENT CELL DEATH | NEUROSEARCH A/S (DK) | 2002-08-22 | — | — | WO | claimed |
| US-20230312612-A1 | HETEROAROMATIC COMPOUNDS FOR ORGANIC ELECTROLUMINESCENT DEVICES | UDC IRELAND LIMITED (IE) | 2023-10-05 | — | — | US | disclosed |
| WO-2022002772-A1 | HETEROAROMATIC COMPOUNDS FOR ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2022-01-06 | — | — | WO | disclosed |
| US-7534505-B2 | Organometallic compounds for use in electroluminescent devices | THE UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2009-05-19 | — | — | US | disclosed |
| WO-2005113704-A2 | LUMINESCENT COMPOUNDS WITH CARBENE LIGANDS | THE UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2005-12-01 | — | — | WO | disclosed |
| US-20050260448-A1 | Novel organometallic compounds for use in electroluminescent devices | UNIVERSAL DISPLAY CORPORATION | 2005-11-24 | — | — | US | disclosed |
| US-20040077634-A1 | Treatment of diseases characterized by excessive or insufficient cell death | NEUROSEARCH A/S (DK) | 2004-04-22 | — | — | US | disclosed |
| EP-1361874-A1 | TREATMENT OF DISEASES CHARACTERIZED BY EXCESSIVE OR INSUFFICIENT CELL DEATH | NEUROSEARCH A/S (DK) | 2003-11-19 | — | — | EP | disclosed |
| WO-2002064128-A1 | TREATMENT OF DISEASES CHARACTERIZED BY EXCESSIVE OR INSUFFICIENT CELL DEATH | NEUROSEARCH A/S (DK) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077634-A1 | Treatment of diseases characterized by excessive or insufficient cell death | APAF1, CASP9, AIFM1 | HTT 266/4885FGFR1 4070/4885CYP11B1 569/4885 |
| US-20230312612-A1 | HETEROAROMATIC COMPOUNDS FOR ORGANIC ELECTROLUMINESCENT DEVICES | DDT, EED, CTCF | HTT 191/4885FGFR1 4356/4885CYP11B1 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.